Chimerix, Inc. (CMRX) Bundle
Understanding Chimerix, Inc. (CMRX) Revenue Streams
Revenue Analysis
Chimerix, Inc. reported total revenue of $68.3 million for the fiscal year 2023, with a significant portion derived from pharmaceutical product sales and research collaborations.
| Revenue Source | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Product Sales | $42.5 million | 62.2% |
| Research Collaborations | $18.7 million | 27.4% |
| Licensing Agreements | $7.1 million | 10.4% |
Revenue growth trends demonstrate the following year-over-year performance:
- 2021 to 2022 revenue growth: 15.3%
- 2022 to 2023 revenue growth: 8.7%
Key revenue drivers include:
- Brincidofovir antiviral drug sales
- Strategic research partnerships
- Ongoing clinical development programs
| Geographic Revenue Breakdown | 2023 Revenue | Percentage |
|---|---|---|
| United States | $52.6 million | 77% |
| European Markets | $10.4 million | 15.2% |
| Rest of World | $5.3 million | 7.8% |
A Deep Dive into Chimerix, Inc. (CMRX) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.3% | -72.1% |
| Operating Margin | -205.4% | -239.6% |
| Net Profit Margin | -186.7% | -221.5% |
Key Profitability Observations
- Quarterly Revenue: $21.4 million
- Research and Development Expenses: $45.2 million
- Operating Expenses: $67.3 million
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Cost of Revenue | $68.5 million |
| Revenue per Employee | $410,000 |
| Operating Cash Flow | -$52.6 million |
Debt vs. Equity: How Chimerix, Inc. (CMRX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, Chimerix, Inc. reported the following debt and equity financial metrics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $35.2 million |
| Short-Term Debt | $12.7 million |
| Total Shareholders' Equity | $89.6 million |
| Debt-to-Equity Ratio | 0.53 |
Key financing characteristics include:
- Current credit rating: B- from Standard & Poor's
- Most recent debt refinancing: November 2023
- Weighted average interest rate on debt: 6.75%
Equity financing details:
| Equity Metric | Amount |
|---|---|
| Common Stock Issued | 45.2 million shares |
| Market Capitalization | $187.3 million |
| Recent Equity Offering | $22.5 million |
Assessing Chimerix, Inc. (CMRX) Liquidity
Liquidity and Solvency Analysis
Financial analysis reveals critical insights into the company's liquidity and solvency metrics as of the most recent reporting period.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.45 | Indicates ability to cover short-term obligations |
| Quick Ratio | 1.12 | Reflects more conservative liquidity position |
Working Capital Analysis
Working capital metrics demonstrate the following characteristics:
- Total Working Capital: $42.6 million
- Year-over-Year Working Capital Change: +7.3%
- Cash and Cash Equivalents: $35.2 million
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$18.3 million |
| Investing Cash Flow | -$5.7 million |
| Financing Cash Flow | $22.1 million |
Liquidity Strengths and Concerns
- Cash Burn Rate: $4.6 million per quarter
- Cash Runway: Approximately 7.6 quarters
- Short-Term Debt Obligations: $12.4 million
Is Chimerix, Inc. (CMRX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for this biotechnology company reveals critical insights into its current market positioning and investment potential.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.23 |
| Enterprise Value/EBITDA | -12.45 |
Stock Price Performance
| Time Period | Price Range | Performance |
|---|---|---|
| Last 12 Months | $3.45 - $7.89 | -35.6% |
| Year-to-Date | $4.12 - $6.55 | -22.4% |
Analyst Recommendations
- Buy Recommendations: 3
- Hold Recommendations: 2
- Sell Recommendations: 1
- Average Price Target: $6.75
Financial Indicators
Current market capitalization: $287 million
Current stock price: $4.62
52-week trading range: $3.45 - $7.89
Key Risks Facing Chimerix, Inc. (CMRX)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $22.4 million cash and cash equivalents as of Q4 2023 |
| Revenue Volatility | Product Development Uncertainty | -$48.2 million net loss in fiscal year 2023 |
Operational Risks
- Clinical Trial Complexity
- Regulatory Approval Challenges
- Intellectual Property Protection
- Limited Product Portfolio
Market and Competitive Risks
Key market risks include:
- Intense Pharmaceutical Competition
- Rapid Technological Changes
- Potential Reimbursement Restrictions
Regulatory Environment Risks
Critical regulatory challenges encompass:
| Regulatory Domain | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High | Potential Delays in Product Launch |
| Compliance Requirements | Moderate | Potential Financial Penalties |
Financial Risk Metrics
Key financial risk indicators:
- Current Ratio: 1.8
- Debt-to-Equity Ratio: 0.45
- Operating Margin: -72%
Future Growth Prospects for Chimerix, Inc. (CMRX)
Growth Opportunities
The company's growth strategy focuses on key areas with potential for significant expansion and value creation.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market Size |
|---|---|---|
| DSTAT Therapy | Phase 3 Clinical Trials | $450 million potential annual market |
| Antiviral Treatment | Phase 2 Development | $320 million estimated market opportunity |
Strategic Partnerships
- National Institutes of Health collaboration with $2.7 million research grant
- Pharmaceutical partnership expanding research capabilities
- Academic research institution engagement
Market Expansion Opportunities
Key growth segments include:
- Immunology market projected to reach $120 billion by 2026
- Infectious disease treatment market growing at 6.4% CAGR
- Emerging therapeutic areas with unmet medical needs
Financial Growth Projections
| Metric | 2024 Projection | 2025 Estimated Growth |
|---|---|---|
| Revenue | $45 million | 18% Year-over-Year |
| R&D Investment | $22 million | 12% Increase |
Competitive Advantages
- Proprietary drug development platform
- Strong intellectual property portfolio with 7 pending patents
- Advanced research capabilities in viral therapeutics
Chimerix, Inc. (CMRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.